开窗与平行支架腔内修复近肾、肾上及胸腹主动脉瘤的两年单中心评估
两组围手术期死亡率、再干预率及24个月生存率无显著差异,平行支架组因内漏再干预更多。平行支架是开窗支架的安全可行替代方案。
要点
- FEVAR与平行支架的围手术期死亡率、分支再干预率及24个月生存率相当。
- 平行支架组因内漏再干预5例(13.1%),FEVAR组无内漏相关再干预。
- 平行支架可用于更紧急或解剖更复杂、不适合FEVAR的患者。
核心结论
- 平行支架与开窗支架在近肾、肾上及胸腹主动脉瘤腔内治疗中具有可接受且相当的死亡率和通畅率。
- 平行支架是复杂主动脉瘤疾病中开窗支架的安全可行替代方案,尽管常治疗更紧急和解剖更复杂的患者。
研究设计与样本
- 单中心回顾性 review,连续纳入2014年8月至2017年3月接受复杂腔内修复的近肾、肾上或胸腹主动脉瘤患者,排除破裂动脉瘤。
关键数值与推荐
- 平行支架组因内漏再干预5例(2例I型、2例III型、1例gutter内漏),占13.1%;FEVAR组无内漏相关再干预。
临床怎么用
- 对于近肾、肾上及胸腹主动脉瘤,平行支架可作为开窗支架的替代选择,尤其适用于更紧急或解剖复杂不适合FEVAR的患者。
- 需关注平行支架组内漏相关再干预风险,术后影像随访中应警惕I型、III型及gutter内漏。
局限性
- 治疗方式由单一位外科医生根据解剖和紧急程度决定,存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite numerous recent pivotal and small-scale trials, real-world endovascular management of juxtarenal aneurysms (JRA), suprarenal aneurysms (SRA), and thoracoabdominal aortic aneurysms (TAAA) remains challenging without consensus best practices. This study evaluated the mortality, graft patency, renal function, complication, and reintervention rates for fenestrated and parallel endografts in complex aortic aneurysms repairs. METHODS: This retrospective review of consecutive included patients with JRA, SRA, or TAAA who underwent complex endovascular repair from August 2014 to March 2017 at one high-volume institution. Treatment modality was a single surgeon decision based on patients anatomy and the urgency of the repair. Patient demographics, hospital course, and follow-up visits inclusive of imaging were analyzed. Ruptured aneurysms were excluded. Survival rates and outcomes were determined using the Kaplan-Meier method with log-rank tests. RESULTS: Seventy complex endovascular aortic repairs were performed; 38 patients with TAAA were treated with snorkel/sandwich parallel endografts (21 celiac, 28 superior mesenteric arteries, 58 renal arteries) and 32 patients with JRA/SRA were treated by fenestrated endovascular aneurysm repair (FEVAR) with 94 total fenestrations (2 celiac, 30 SMA, 62 renal). The mean patient age was 74.8 ± 10.0 years. Sixty percent were male, and the mean aortic aneurysm diameter was 6.0 ± 1.4 cm. Perioperative mortality was 3.1% (1/32) for FEVAR compared with 2.6% (1/38) for parallel endografts (P = .9). All-cause reintervention rates were 15.6% in FEVAR (5/32) vs 23.6% with parallel endografts (9/38; P = .4). Branch reintervention rates per each branch endograft were 4.3% for FEVAR (4/94; 2 renal stent occlusions, 1 colonic ischemia without technical issue found on reintervention, 1 perinephric hematoma) vs 3.7% for parallel endografts (4/107; 2 renal and 1 celiac stent thromboses, and 1 renal stent kink; P = .41). The endograft branch thrombosis rate was 2.1% in FEVAR (2/94) vs 2.7% in parallel endografts (3/109; P = .77). Reinterventions owing to endoleaks were performed in five patients (2 type I, 2 type III, and 1 gutter endoleak; 13.1%) with parallel grafts vs no endoleak reinterventions in FEVAR. The overall survival and freedom from aneurysm-related mortality at 24 months was 78% and 96.9% in FEVAR vs 73% and 93.4% for parallel endografts (P = .8 and P = .6). The median follow-up was 12 months (range, 1-32 months). CONCLUSIONS: Parallel and fenestrated endografts have acceptable and comparable mortality and patency rates in endovascular treatment of JRA, SRA, and TAAA. This study reaffirms that parallel endografts are a safe and viable alternative to fenestrated devices for complex aortic aneurysmal disease despite often treating more urgent patients and more complicated anatomy unable to be treated with FEVAR.
引用
- Bannazadeh M, Beckerman WE, Korayem AH, et al. Two-year evaluation of fenestrated and parallel branch endografts for the treatment of juxtarenal, suprarenal, and thoracoabdominal aneurysms at a single institution. J Vasc Surg. 2019. PMID: 31718954. doi:10.1016/j.jvs.2019.03.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。